$Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial$

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

<p><strong>Background</strong> Evidence indicates that fractional doses of yellow fever vaccine are safe and sufficiently immunogenic for use during yellow fever outbreaks. However, there are no data on the generalisability of this observation to populations living with HIV. Theref...

Full description

Bibliographic Details
Main Authors:	Kimathi, D, Juan-Giner, A, Orindi, B, Grantz, KH, Bob, NS, Cheruiyot, S, Hamaluba, M, Kamau, N, Fall, G, Dia, M, Mosobo, M, Moki, F, Kiogora, K, Chirro, O, Thiong'o, A, Mwendwa, J, Guantai, A, Karanja, HK, Gitonga, J, Mugo, D, Ramko, K, Faye, O, Sanders, EJ, Grais, RF, Bejon, P, Warimwe, GM
Format:	Journal article
Language:	English
Published:	Elsevier 2023

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

Similar Items